You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommends Namuscla for NHS to treat genetic disorder

NICE has published draft guidance which recommends a rebranded form of the drug mexiletine (Namuscla), for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders (NDM).